Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 11, 2015, Pages 1495-1515

  Ali, Sajjadh Mj ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

blood pressure; endothelium; preeclampsia; pregnancy; vascular smooth muscle

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSIN II; ANGIOTENSINOGEN; BLOOD CLOTTING FACTOR 5; BRADYKININ; CATECHOL METHYLTRANSFERASE; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 6; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PROSTACYCLIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; THROMBOXANE A2; VASCULOTROPIN; BIOLOGICAL MARKER;

BLOOD PRESSURE; BRAIN EDEMA; CALCIUM CELL LEVEL; CARDIOVASCULAR RISK; CYTOTROPHOBLAST; ENDOTHELIAL DYSFUNCTION; ENDOTHELIOSIS; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; GENOME IMPRINTING; HELLP SYNDROME; HEREDITY; HUMAN; HYPOXIA; IMMUNE RESPONSE; MATERNAL HYPERTENSION; NONHUMAN; PREECLAMPSIA; PROTEINURIA; REVIEW; SEIZURE; SMOOTH MUSCLE CONTRACTION; TH1 CELL; TH2 CELL; VASCULAR DISEASE; VASCULAR REMODELING; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VISUAL DISORDER; ANIMAL; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY; VASCULAR ENDOTHELIUM;

ANIMALS; BIOMARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HELLP SYNDROME; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; PLACENTA; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 84947033542     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1067684     Document Type: Review

References (106)

1. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005;46(6):1243-9
2. Sheppard SJ, Khalil RA. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disord Drug Targets 2010;10(1):33-52
3. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008;59:61-78
4. Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009;53(2):399-403
5. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001;357(9251):209-15
6. Founds SA, Conley YP, Lyons-Weiler JF, et al. Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 2009;30(1):15-24
7. van Dijk M, Oudejans CB. STOX1: key player in trophoblast dysfunction underlying early onset preeclampsia with growth retardation. J Pregnancy 2011;2011:521826
8. Fenstad MH, Johnson MP, Loset M, et al. STOX2 but not STOX1 is differentially expressed in decidua from pre-eclamptic women: data from the Second Nord-Trondelag Health Study. Mol Hum Reprod 2010;16(12):960-8
9. Rigourd V, Chauvet C, Chelbi ST, et al. STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One 2008;3(12):e3905
10. Doridot L, Passet B, Mehats C, et al. Preeclampsia-like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment. Hypertension 2013;61(3):662-8
11. Papazoglou D, Galazios G, Koukourakis MI, et al. Association of-634G/C and 936C/T polymorphisms of the vascular endothelial growth factor with spontaneous preterm delivery. Acta Obstet Gynecol Scand 2004;83(5):4615
12. Rajakumar A, Michael HM, Daftary A, et al. Proteasomal activity in placentas from women with preeclampsia and intrauterine growth restriction: implications for expression of HIF-alpha proteins. Placenta 2008;29(3):290-9
13. Ciarmela P, Boschi S, Bloise E, et al. Polymorphisms of FAS and FAS ligand genes in preeclamptic women. Eur J Obstet Gynecol Reprod Biol 2010;148(2):144-6
14. Winn VD, Gormley M, Paquet AC, et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 2009;150(1):452-62
15. Bernstein IM, Ziegler W, Stirewalt WS, et al. Angiotensinogen genotype and plasma volume in nulligravid women. Obstet Gynecol 1998;92(2):171-3
16. Bernstein IM, Meyer MC, Osol G, Ward K. Intolerance to volume expansion: A theorized mechanism for the development of preeclampsia. Obstet Gynecol 1998;92(2):306-8
17. Zubor P, Dokus K, Zigo I, et al. TNF alpha G308A gene polymorphism has an impact on renal function, microvascular permeability, organ involvement and severity of preeclampsia. Gynecol Obstet Invest 2014;78(3):150-61
18. Sowmya S, Sri Manjari K, Ramaiah A, et al. Interleukin 10 gene promoter polymorphisms in women with earlyonset pre-eclampsia. Clin Exp Immunol 2014;178(2):334-41
19. Ward K. Searching for genetic factors underlying pre-eclampsia: recent progress and persistent challenges. Minerva Ginecol 2008;60(5):399-419
20. Tan CY, Chong YS, Loganath A, et al. Possible gene-gene interaction of KIR2DL4 with its cognate ligand HLAG in modulating risk for preeclampsia. Reprod Sci 2009;16(12):1135-43
21. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001;344(12):867-72
22. Caughey AB, Stotland NE, Washington AE, Escobar GJ. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol 2005;106(1):156-61
23. Saito S, Shiozaki A, Nakashima A, et al. The role of the immune system in preeclampsia. Mol Aspects Med 2007;28(2):192-209
24. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365(9461):785-99
25. von Dadelszen P, Magee LA, Krajden M, et al. Levels of antibodies against cytomegalovirus and Chlamydophila pneumoniae are increased in early onset pre-eclampsia. BJOG 2003;110(8):725-30
26. Trogstad LI, Eskild A, Bruu AL, et al. Is preeclampsia an infectious disease? Acta Obstet Gynecol Scand 2001;80(11):1036-8
27. Geva E, Ginzinger DG, Zaloudek CJ, et al. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 2002;87(9):4213-24
28. McMaster MT, Zhou Y, Fisher SJ. Abnormal placentation and the syndrome of preeclampsia. Semin Nephrol 2004;24(6):540-7
29. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355(10):992-1005
30. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111(5):649-58
31. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36
32. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004;95(9):884-91
33. Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198(2):200; e1-7
34. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198(4):428; e1-6
35. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12(6):642-9
36. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998;40(2):102-11
37. Orshal JM, Khalil RA. Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 2004;43(2):434-44
38. Mellembakken JR, Aukrust P, Olafsen MK, et al. Activation of leukocytes during the uteroplacental passage in preeclampsia. Hypertension 2002;39(1):155-60
39. Wang Y, Gu Y, Philibert L, Lucas MJ. Neutrophil activation induced by placental factors in normal and preeclamptic pregnancies in vitro. Placenta 2001;22(6):560-5
40. Nakamura M, Sekizawa A, Purwosunu Y, et al. Cellular mRNA expressions of antioxidant factors in the blood of preeclamptic women. Prenat Diagn 2009;29(7):691-6
41. Tsukimori K, Fukushima K, Tsushima A, Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. Hypertension 2005;46(4):696-700
42. Yang G, Chang L, Alexander JS, et al. Chymotrypsin-like protease (chymase) mediates endothelial activation by factors derived from preeclamptic placentas. Reprod Sci 2009;16(9):905-13
43. Anguiano-Robledo L, Reyes-Melchor PA, Bobadilla-Lugo RA, et al. Renal angiotensin-II receptors expression changes in a model of preeclampsia. Hypertens Pregnancy 2007;26(2):151-61
44. AbdAlla S, Abdel-Baset A, Lother H, et al. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 2005;26(2-3):185-92
45. Anton L, Merrill DC, Neves LA, et al. The uterine placental bed Renin-Angiotensin system in normal and preeclamptic pregnancy. Endocrinology 2009;150(9):4316-25
46. Bakker WW, Henning RH, van Son WJ, et al. Vascular contraction and preeclampsia: downregulation of the Angiotensin receptor 1 by hemopexin in vitro. Hypertension 2009;53(6):959-64
47. Bobst SM, Day MC, Gilstrap LC III, et al. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am J Hypertens 2005;18(3):330-6
48. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009;54(4):905-9
49. Kanasaki K, Palmsten K, Sugimoto H, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008;453(7198):1117-21
50. Bar J, Kaplan B, Wittenberg C, et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant 1999;14(5):1129-32
51. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007;18(8):2281-4
52. Alexander BT, Kassab SE, Miller MT, et al. Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension 2001;37(4):1191-5
53. Khalil RA, Crews JK, Novak J, et al. Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. Hypertension 1998;31(5):1065-9
54. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endotheliumdependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension 2000;35(1 Pt 2):367-72
55. Suzuki Y, Hattori T, Kajikuri J, et al. Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia. J Physiol 2002;545(Pt 1):269-77
56. Majed BH, Khalil RA. Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 2012;64(3):540-82
57. Bowen RS, Zhang Y, Gu Y, et al. Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta 2005;26(5):402-9
58. Zhao S, Gu Y, Lewis DF, Wang Y. Predominant basal directional release of thromboxane, but not prostacyclin, by placental trophoblasts from normal and preeclamptic pregnancies. Placenta 2008;29(1):81-8
59. Luksha L, Nisell H, Luksha N, et al. Endothelium-derived hyperpolarizing factor in preeclampsia: heterogeneous contribution, mechanisms, and morphological prerequisites. Am J Physiol Regul Integr Comp Physiol 2008;294(2):R510-19
60. Martin D, Conrad KP. Expression of endothelial nitric oxide synthase by extravillous trophoblast cells in the human placenta. Placenta 2000;21(1):23-31
61. Mazzuca MQ, Li W, Reslan OM, et al. Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy. Hypertension 2014;64(3):632-43
62. Seki H, Kuromaki K, Takeda S, et al. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia. Hypertens Pregnancy 1999;18(2):157-64
63. Murphy JG, Herrington JN, Granger JP, Khalil RA. Enhanced [Ca2+]i in renal arterial smooth muscle cells of pregnant rats with reduced uterine perfusion pressure. Am J Physiol Heart Circ Physiol 2003;284(1):H393-403
64. Kanashiro CA, Cockrell KL, Alexander BT, et al. Pregnancy-associated reduction in vascular protein kinase C activity rebounds during inhibition of NO synthesis. Am J Physiol Regul Integr Comp Physiol 2000;278(2):R295-303
65. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103(7):945-52
66. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002;39(2):245-50
67. Montagnana M, Lippi G, Albiero A, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 2009;23(2):88-92
68. Li W, Mata KM, Mazzuca MQ, Khalil RA. Altered matrix metalloproteinase-2 and-9 expression/activity links placental ischemia and antiangiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol 2014;89(3):370-85
69. Jeyabalan A, Novak J, Doty KD, et al. Vascular matrix metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin. Endocrinology 2007;148(1):189-97
70. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy 2003;22(2):143-8
71. Purwosunu Y, Sekizawa A, Okazaki S, et al. Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol 2009;200(4):386; e1-7
72. Bainbridge SA, Roberts JM, von Versen-Hoynck F, et al. Uric acid attenuates trophoblast invasion and integration into endothelial cell monolayers. Am J Physiol Cell Physiol 2009;297(2):C440-50
73. Kim SY, Ryu HM, Yang JH, et al. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia. J Korean Med Sci 2006;21(3):452-6
74. Staff AC, Braekke K, Harsem NK, et al. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2005;122(1):33-9
75. Hunt BJ, Missfelder-Lobos H, Parra-Cordero M, et al. Pregnancy outcome and fibrinolytic, endothelial and coagulation markers in women undergoing uterine artery Doppler screening at 23 weeks. J Thromb Haemost 2009;7(6):955-61
76. Laverriere A, Landau R, Charvet I, et al. GRP78 as a marker of pre-eclampsia: an exploratory study. Mol Hum Reprod 2009;15(9):569-74
77. Zeng X, Sun Y, Yang HX, et al. Plasma level of soluble c-Met is tightly associated with the clinical risk of preeclampsia. Am J Obstet Gynecol 2009;201(6):618; e1-7
78. Zafarmand MH, Franx A, Sabour S, et al. The M235T variant of the angiotensinogen gene is related to development of self-reported hypertension during pregnancy: The Prospect-EPIC cohort study. Hypertens Res 2008;31(7):1299-305
79. Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008;112(9):3615-23
80. Buurma AJ, Turner RJ, Driessen JH, et al. Genetic variants in pre-eclampsia: A meta-analysis. Hum Reprod Update 2013;19(3):289-303
81. Piccoli JC, Gottlieb MG, Castro L, et al. Association between 894G>T endothelial nitric oxide synthase gene polymorphisms and metabolic syndrome. Arq Bras Endocrinol Metabol 2008;52(8):1367-73
82. Fitzpatrick E, Goring HH, Liu H, et al. Fine mapping and SNP analysis of positional candidates at the preeclampsia susceptibility locus (PREG1) on chromosome 2. Hum Biol 2004;76(6):849-62
83. Brinkman-Van der Linden EC, Hurtado-Ziola N, Hayakawa T, et al. Human-specific expression of Siglec-6 in the placenta. Glycobiology 2007;17(9):922-31
84. Chen W, Khalil RA. Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. Am J Physiol Regul Integr Comp Physiol 2008;295(6):R1962-72
85. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007;50(6):1142-7
86. LaMarca B, Speed J, Fournier L, et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension 2008;52(6):1161-7
87. Davis JR, Giardina JB, Green GM, et al. Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-alpha-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol 2002;282(2):R390-9
88. LaMarca BB, Bennett WA, Alexander BT, et al. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. Hypertension 2005;46(4):1022-5
89. Alexander BT, Cockrell KL, Massey MB, et al. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens 2002;15(2 Pt 1):170-5
90. Kassab S, Miller MT, Hester R, et al. Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. Hypertension 1998;31(1 Pt 2):315-20
91. Souza CO, Peracoli MT, Weel IC, et al. Hepatoprotective and anti-inflammatory effects of silibinin on experimental preeclampsia induced by L-NAME in rats. Life Sci 2012;91(5-6):159-65
92. Shaarawy M, Al-Sokkary F, Sheba M, et al. Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia. Int J Gynaecol Obstet 2005;88(2):112-17
93. Stepan H, Geide A, Faber R. Soluble FMS-like tyrosine kinase 1. N Engl J Med 2004;351(21):2241-2
94. Hayashi M, Ueda Y, Yamaguchi T, et al. Tumor necrosis factor-alpha in the placenta is not elevated in pre-eclamptic patients despite its elevation in peripheral blood. Am J Reprod Immunol 2005;53(3):113-19
95. Casart YC, Tarrazzi K, Camejo MI. Serum levels of interleukin-6, interleukin-1beta and human chorionic gonadotropin in pre-eclamptic and normal pregnancy. Gynecol Endocrinol 2007;23(5):300-3
96. Ranta V, Viinikka L, Halmesmaki E, Ylikorkala O. Nitric oxide production with preeclampsia. Obstet Gynecol 1999;93(3):442-5
97. Mills JL, DerSimonian R, Raymond E, et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: A multicenter prospective study. JAMA 1999;282(4):356-62
98. Brosnihan KB, Neves LA, Anton L, et al. Enhanced expression of Ang-(1-7) during pregnancy. Braz J Med Biol Res 2004;37(8):1255-62
99. Wallace K, Richards S, Dhillon P, et al. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension 2011;57(5):949-55
100. Gilbert JS, Ryan MJ, LaMarca BB, et al. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008;294(2):H541-50
101. Verlohren S, Niehoff M, Hering L, et al. Uterine vascular function in a transgenic preeclampsia rat model. Hypertension 2008;51(2):547-53
102. LaMarca BB, Cockrell K, Sullivan E, et al. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 2005;46(1):82-6
103. Murphy JG, Fleming JB, Cockrell KL, et al. [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. Am J Physiol Regul Integr Comp Physiol 2001;280(1):R87-99
104. Lim JH, Kim SY, Park SY, et al. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008;111(6):1403-9
105. Baumann MU, Bersinger NA, Mohaupt MG, et al. First-trimester serum levels of soluble endoglin and soluble FMS-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008;199(3):266; e1-6
106. Chavarria ME, Lara-Gonzalez L, Garcia-Paleta Y, et al. Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol 2008;137(2):157-64